SCHEMBL10102653

SCHEMBL10102653

Cc1cccc(-c2nc3ccc(C(F)(F)F)cc3cc2CCCO)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.40
KCNH2 Q12809 1/20 0.40
DHODH Q02127 1/20 0.39
DHFR P00374 4/20 0.38
TYMS P04818 1/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPK14 Q16539 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TLR8 Q9NR97 1/20 0.35
MDM2 Q00987 3/20 0.35
HPGD P15428 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10107977 0.87 NPBWR1 (0.43) CTSKKCNH2DHODHDHFRTYMS
SCHEMBL3383001 0.87 DHODH (0.45) CTSKKCNH2DHODHDHFRTYMS
SCHEMBL10102646 0.84 CTSK (0.47) CTSKKCNH2NAMPT
SCHEMBL10102652 0.82 TRPA1 (0.43) CTSKKCNH2DHODHDHFRTYMS
SCHEMBL13005263 0.81 DHFR (0.40) CTSKKCNH2DHODHDHFRTYMS
SCHEMBL13005264 0.80 KDM4E (0.39) CTSKKCNH2DHODHDHFRTYMS
SCHEMBL10102671 0.80 DHODH (0.46) KCNH2DHODHDHFRTYMSKDM4E
SCHEMBL10102644 0.79 GPBAR1 (0.42) CTSKKCNH2KDM4EBACE1
SCHEMBL10102657 0.79 NPBWR1 (0.44) CTSKKCNH2DHODHKDM4ETRPV1
SCHEMBL13005210 0.78 AKT1 (0.39) DHODHKDM4EALDH1A1CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B CTSK 3797/4885KCNH2 1709/4885DHODH 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.